Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

AB Sciex (d/b/a Sciex). (1/21/21). "Press Release: Sciex Acquires Intabio, a Developer of Precision Solutions for Biotherapeutic Analysis through Imaged cIEF-MS". Framingham, MA.

Organisations Organisation AB Sciex (Danaher, Framingham, MA)
  Group Danaher (Group)
  Organisation 2 Intabio Inc.
  Group Danaher (Group)
Products Product Blaze™ System
  Product 2 mass spectrometry-based analysis of biopharmaceutical
Index term Index term Intabio–Danaher: investment, 202101 acquisition $na of Intabio Inc by Sciex
Persons Person Lowenstein, Inese (Danaher 201709– President at Sciex joined 8/16 before Merck KGaA)
  Person 2 Wu, Lena (Intabio 201709 CEO + Co-Founder)
     


Innovative charged variant analysis accelerates biologic drug development, ensuring drug safety and efficacy


SCIEX a global leader in life science analytical technologies, announced the closing of its acquisition of Intabio, Inc., a privately held company and the developer of the Blaze™ System for biotherapeutic analysis and quality assessment. Blaze enables the direct coupling of imaged cIEF charge variant analysis with high-resolution mass spectrometry to detect intact proteins.

“Intabio’s technology is an excellent fit with SCIEX. With our combined knowledge of the biopharma market, capillary electrophoresis and mass spectrometry, we believe we can significantly simplify how our customers bring life-saving drugs to market faster,” said Inese Lowenstein, President at SCIEX.

Imaged cIEF-MS technology provides a groundbreaking solution for those looking for better and faster tools to characterize their increasingly complex biomolecules. The Blaze System coupled to high-resolution mass spectrometry provides a streamlined approach that can reduce lengthy sample prep and deliver increased sample throughput. This results in much needed cost and time savings for biopharma analytical labs.

“This acquisition creates a synergy of technology and scale to deliver solutions that eliminate many workflow bottlenecks our customers struggle with in biopharmaceutical drug development,” added Lena Wu, Ph.D., CEO and co-founder of Intabio. "The Intabio team is excited by this acquisition and especially the ability to leverage SCIEX expertise and scale in global sales, support and manufacturing.”

Intabio associates and products will transition into SCIEX while continuing to operate from its existing facilities in Fremont, California. Financial terms of the transaction were not disclosed.


About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, please visit sciex.com

SCIEX social: @SCIEXnews, LinkedIn, and Facebook.

Advances in human wellness depend on the power of precise science.


About Intabio

Intabio, Inc. is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio's first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins.


The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.

© 2021 DH Tech. Dev. Pte. Ltd.


Contact Information

Lulu VanZandt
Program Manager, Brand, Public Relations and Social Media, SCIEX
lulu.vanzandt@sciex.com
+1 (508) 383-7163
M: +1 (508) 782-9484

   
Record changed: 2021-02-27

Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for Danaher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [iito] Fighting Customers 650x80px




» top